BERKELEY, Calif. and MAINZ, Germany, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the closing of its previously announced registered direct offering with several institutional investors to purchase $5.0 million of its ordinary shares (or pre-funded warrants to purchase ordinary shares in lieu thereof) and warrants to purchase ordinary shares. The combined effective purchase price for each ordinary share (or pre-funded warrant) and associated warrant to purchase one ordinary share was $1.20.
Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.
The registered direct offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-269091) declared effective by the U.S. Securities and Exchange Commission (the "SEC") on January 6, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade, 29th floor, New York, NY 10007, by telephone at (929) 833-1246 or by email at info@titanpartnersgrp.com.
This press release shall not constitute an offer to sell or the solicitation of ...